Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties.

Insilico Medicine Raises $60 Million In Series D Financing To Advance Pipeline And Launch Ai-Powered Drug Discovery Robotics Laboratory

Description

Company Information

Funding Insights

Insilico Medicine Raises $60 Million In Series D Financing To Advance Pipeline And Launch Ai-Powered Drug Discovery Robotics Laboratory

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information